PATH's Malaria Vaccine Initiative names new R&D director
King has worked as a scientist in both the public and private sectors for more than 25 years, and most recently served as vice president of the International AIDS Vaccine Initiative. He once partnered with MVI while developing multicomponent malaria vaccine approaches as senior vice president of research at GenVec, Inc.
"We are tremendously fortunate to have Dr. King join MVI," Ashley J. Birkett, the director of MVI, said. "This is a pivotal time for us, as we accelerate efforts to develop a future generation of vaccines that will block the transmission of the malaria parasite between people and mosquitoes. His appointment rounds out the leadership of our R&D efforts at MVI and I couldn't be happier."
King is listed as an inventor of 12 patents, and received a Ph. D. in biochemistry from Johns Hopkins University.
"Advancing new treatments and preventions have been a life-long passion and I am excited to be on the cutting edge of the malaria vaccine development field," King said. "I can't wait to get started."
MVI was established through an initial grant from the Bill & Melinda Gates Foundation and works to develop malaria vaccines and improve their accessibility.